Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dengue virus serotype 1 (DENV-1) is one of four antigenically distinct serotypes of the dengue virus, a mosquito-borne pathogen belonging to the genus *Flavivirus*. DENV-1 is an enveloped, positive-sense, single-stranded RNA virus. It is transmitted primarily by *Aedes* mosquitoes and can cause a spectrum of disease in humans ranging from mild febrile illness to severe hemorrhagic fever and shock syndrome. Entry into host cells involves initial binding to specific receptors like the 37/67-kDa high-affinity laminin receptor and heparan sulfate on the cell surface. DENV‑1 can be detected using molecular assays such as real-time RT-PCR. Infection with DENV-1 can result in asymptomatic infection or classic dengue fever. Distinct clinical features associated with DENV‑1 include a higher likelihood of red eyes compared to other serotypes. Sequential infections by different dengue virus serotypes increase the risk for more severe disease due to immune enhancement mechanisms.
Viral infection and replication within host cells, leading to inflammation and potential vascular leakage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dengue Virus Serotype 1 (DENV-1).